Slide 1: Q2/H1 2024 Results Presentation
Q2/H1 2024 Results Presentation Dietmar Siemssen, CEO Dr. Bernd Metzner, CFO Düsseldorf, July 11, 2024
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Highlights Q2 2024
Highlights Q2 2024 Dietmar Siemssen (CEO)
Slide 4: Strategic Partner of Choice for the Global Pharma and Biotech Industry
Strategic Partner of Choice for the Global Pharma and Biotech Industry Digital Therapy Containment Support Solutions Improve patient’s health outcome Bring the drug to the patient Drug Delivery Systems Bring the drug into the patient 4 11-Jul-2024 Gerresheimer AG - Q2/H1 2024 Results Presentation
Slide 5: On Track for Sustainable Profitable Growth and Value Creation
On Track for Sustainable Profitable Growth and Value Creation Q2 2024: Performance in Line with Previous Year Organic Development: − Bormioli Acquisition Revenue growth: Adj. EBITDA growth: Announced in May − Gearing up for a +0.7% +0.8% 2024 strong H2 2024 Adj. EPS: − P&D showing − Guidance confirm
Slide 6: Accelerate Execute Innovate
Leveraging on Unique Business Opportunities to Drive Long-Term Growth Key Priorities in FY 2024 Accelerate sustainable, profitable growth by consistently increasing the revenue share of systems and solutions for biologics and injectables Accelerate — Execute ongoing growth projects and operational e
Slide 7: The New Gerresheimer – Solid Foundation Platform Bolstered With Growth Accelerators
The New Gerresheimer – Solid Foundation Platform Bolstered With Growth Accelerators Growth Accelerators Ready-to-Fill High Value High Value Devices Vials & Cartridges Pharma Plastics Digital Syringes Own IP-Solutions (EZ-fill Smart ) Solutions Solid Foundation Platform Pharma Plastics & Prescription
Slide 8: Bormioli Pharma Plastics complements our System and Solution Portfolio
Bormioli Pharma Plastics complements our System and Solution Portfolio 1. Enabling Full Solution Offerings for Pharma Plastics and Containment Systems Gerresheimer Plastic 2. Truly Complimentary Pharma Plastics Offering - Creation of a Global One-Stop-Shop for Pharma Customers Packaging + 3. Own Mou
Slide 9: Systems Integration Enhancing Customer Value
Systems Integration Enhancing Customer Value Enabling Full Solutions for Pharma Containment, e.g. for Bottles PET & Glass bottles Accessories for PET & Glass bottles PPP Product Database • Complete regulatory support for integrated solutions • Support for internal documentation, testing and approval
Slide 10: Performance in Line with Previous Year
Performance in Line with Previous Year Dr. Bernd Metzner (CFO)
Slide 11: Q2 2024: Performance in-line with Previous Year
Q2 2024: Performance in-line with Previous Year Operational View on KPIs in Q2 2024 Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) Organic growth yoy: Organic growth yoy: Organic growth yoy: +0.7% +0.8% -3.1% 502 107 107 1.30 500 1.24 Q2 2023 Q2 2024 Q2 2023 Q2 2024 Q2 2023 Q2 2024 11
Slide 12: P&D with continued margin improvement
P&D with continued margin improvement Operational View on KPIs in Q2 2024 by Division Organic yoy In EUR m & margin Revenues Adj. EBITDA +6.7% +12.4% 283 79 Significant margin improvement by 140bps 265 69 27.7% ▪ Organic revenue growth of 6.7% driven by strong demand for medical P&D 26.3% systems ▪
Slide 13: Reconciliation Q2 2024
Reconciliation Q2 2024 Reported and Adjusted Financials Q2 2024 Q2 2023 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 502.4 502.4 499.6 0.7% EBITDA 102.7 4.7 107.3 107.2 0.8% Depreciation & Amortization -47.0 9.1 -38.0 -37.2 EBIT 55.6 13.8 69.4 70.0 Financial Resu
Slide 14: Free Cashflow Development as Expected
Free Cashflow Development as Expected Cash Flow and Net Financial Debt In EUR m Q2 2024 Q2 2023 Adjusted EBITDA 107.3 107.2 Change in net working capital -49.6 -21.0 Net interest paid -13.8 -9.8 Net taxes paid -9.9 -24.4 Other -26.1 -16.9 Cash flow from operating activities 8.0 35.2 Net capex -76.7
Slide 15: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 16: Accelerate Execute Innovate
Leveraging on Unique Business Opportunities to Drive Long-Term Growth Key Priorities in FY 2024 Accelerate sustainable, profitable growth by consistently increasing the revenue share of systems and solutions for biologics and injectables Accelerate — Execute ongoing growth projects and operational e
Slide 17: Guidance
Guidance FY 2024, FY 2025 and Mid-Term Guidance Revenue Adjusted Adjusted EPS Growth EBITDA Growth FY 2024 5-10% 430-450 8-12% EUR m FY 2025 10-15% ≥ 22% ≥ 10% Margin Mid-term ≥ 10% 23-25% ≥ 10% CAGR Margin CAGR Organic, group level 17 11-Jul-2024 Gerresheimer AG - Q2/H1 2024 Results Presentation
Slide 18: Appendix
oO £ (a) o£ Q OL
Slide 19: Financial Calendar
Financial Calendar Annual General Meeting Gerresheimer Capital 2025 Publication 1rstQuarter Markets Day 2025 Results Publication 4th Quarter/ Full-year 2024 Results Publication 3rd Quarter 2024 Results June 5th, December 2025 April 11th, 2024 2025 February 26th, 2025 October 10th, 2024 19 11-Jul-202
Slide 20: Q2 Revenue & Organic Growth Reconciliation
Q2 Revenue & Organic Growth Reconciliation in EUR m organic growth +0.7% -15.5 17.6 2.0 502.4 500.4 499.6 -2.4 -0.2 1.3 497.2 +6.7% -6.6% Revenue Q2 2023 FX Revenue Q2 P&D PPG GAT HQ, Cons. Revenue Q2 FX Revenue Q2 2024 2023 (organic) 2024 (organic) 20 11-Jul-2024 Gerresheimer AG - Q2/H1 2024 Result
Slide 21: H1 Revenue & Organic Growth Reconciliation
H1 Revenue & Organic Growth Reconciliation in EUR m organic growth +1.7% -31.7 48.6 2.7 968.5 965.8 -3.0 2.0 957.4 -7.5 949.9 +9.9% -6.9% Revenue H1 2023 FX Revenue H1 P&D PPG GAT HQ, Cons. Revenue H1 FX Revenue H1 2024 2023 (organic) 2024 (organic) 21 11-Jul-2024 Gerresheimer AG - Q2/H1 2024 Result
Slide 22: Q2 Adj. EBITDA & Organic Growth Reconciliation
Q2 Adj. EBITDA & Organic Growth Reconciliation in EUR m organic growth margin +0.8% 8.6 -8.6 108.1 -0.8 107.2 0.0 107.2 0.8 107.3 0.1 21.6% +12.4% -17.4% 21.6% Adj. EBITDA FX Adj. EBITDA Q2 P&D PPG GAT HQ, Cons. Adj. EBITDA Q2 FX Adj. EBITDA Q2 2023 2023 (organic) 2024 (organic) Q2 2024 22 11-Jul-20
Slide 23: H1 Adj. EBITDA & Organic Growth Reconciliation
H1 Adj. EBITDA & Organic Growth Reconciliation in EUR m organic growth margin +2.9% -13.2 21.2 -2.1 188.6 -0.5 188.1 -0.5 185.2 -1.9 183.3 19.5% 19.3% +18.3% -14.8% Adj. EBITDA FX Adj. EBITDA H1 P&D PPG GAT HQ, Cons. Adj. EBITDA H1 FX Adj. EBITDA H1 2023 2023 (organic) 2024 (organic) H1 2024 23 11-J
Slide 24: Reconciliation H1 2024
Reconciliation H1 2024 Reported and Adjusted Financials H1 2024 H1 2023 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 968.5 968.5 957.4 1.7% EBITDA 181.0 7.2 188.2 185.2 2.9% Depreciation & Amortization -93.5 18.8 -74.7 -71.2 EBIT 87.5 26.0 113.5 114.0 Financial R
Slide 25: Strong Cash Flow from Operating Activities
Strong Cash Flow from Operating Activities Cash Flow and Net Financial Debt In EUR m H1 2024 H1 2023 Adjusted EBITDA 188.2 185.2 Change in net working capital -73.9 -112.8 Net interest paid -20.0 -15.5 Net taxes paid -16.1 -31.7 Other -43.0 -39.1 Cash flow from operating activities 35.2 -13.9 Net ca
Slide 26: Solid Financial Foundation
Solid Financial Foundation Net Financial Debt & Adjusted EBITDA Leverage Net Financial Debt Maturity Profile In EUR m In EUR m Q2 2024 Q2 2023 Promissory loans Revolving credit facilities (RCF, total volume) Revolving credit facilities1 305 82 200 Promissory loans 792 942 Local borrowings2 33 25 476
Slide 27: innovating for a better life
innovating for a better life